



March 16, 2020
Gene Techno Science Co., Ltd.
Code: 4584 (TSE Mothers)
Masaharu Tani, President & CEO

**Announcement of Establishment of Manufacturing Process for
Master Cell Bank Based on the Business Partnership with
NIKON CORPORATION**

Tokyo, March 16, 2020 – Gene Techno Science Co., Ltd. (“GTS”) announced that its subsidiary company, Advanced Cell Technology and Engineering Ltd. (“ACTE”) has completed development of manufacturing process for a clinical-use Master Cell Bank (“MCB”) from stem cells from human exfoliated deciduous teeth (“SHEDs”). The process development was conducted based on the business alliance with NIKON CORPORATION (“Nikon”).

SHEDs, from which GTS seeks to develop regenerative medicine products, are present in a dental pulp tissue, however, the number of SHEDs in the pulp tissue is limited. Therefore, the process was developed to isolate SHEDs from the pulp tissue and expand them by culturing under a certain condition to manufacture a large number of vials containing SHEDs, or a MCB. SHEDs in a vial of a frozen MCB will be thawed and further expanded to manufacture a regenerative medicine product, which are then administered to patients, as necessary through a Working Cell Bank (WCB).

To advance research and development of regenerative medicine products, stable supply of quality-controlled MCBs are required. With completion of the MCB manufacturing process development, GTS will work to establish a stable supply system of SHEDs with Nikon CeLL innovation Co., Ltd., a wholly-owned subsidiary of Nikon providing a regenerative medicine product contracting development and manufacturing services, entrusted with manufacturing of clinical-use MCBs and establishing of clinical-use WCBs compliant with GCTP and GMP. With these advancements, GTS will accelerate its research and development activities on regenerative medicine products and enrich its pipeline through collaboration with academic and business partners.

The impact on the business results for the fiscal year ending March 2020 is expected to be minimal.

About Gene Techno Science Co., Ltd.

GTS announced GTS 3.0 “Biotech Engineering Company, striving for value creation” a new business stage starting from this fiscal year, which targeted the pediatric disease in addition to the areas GTS has been engaged in such as the orphan disease and intractable disease. By leveraging the knowhow and expertise about biotechnology acquired in the past business activities, GTS is working on the development and provision of new medicines and therapeutic treatment for the purpose of achieving comprehensive healthcare solutions for the patients suffering from these diseases as well as families and caregivers.

Contact:

Gene Techno Science Co., Ltd.

Tel: +81-3-6222-9547 Mail: info@g-gts.com